Drug Profile
Artemether/lumefantrine - Novartis
Alternative Names: Benflumetol; CGP 56697; Co-artemether; COA566; Coartem; Coartem Dispersible; Exafal; Lumefantrine/artemether; RiametLatest Information Update: 22 Nov 2022
Price :
$50
*
At a glance
- Originator Academy of Military Medical Sciences (Beijing)
- Developer Medicines for Malaria Venture; Novartis
- Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Ethanolamines; Fluorenes; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Hemozoin inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malaria
Most Recent Events
- 22 Nov 2022 Phase-III clinical trials in Malaria (In infants, In neonates) in Democratic Republic of the Congo, Mali, Burkina Faso (PO) (Novartis Pharmaceuticals pipeline, November 2022)
- 28 Apr 2022 Novartis plans to submit first regulatory application for Malaria in Switzerland in 2024
- 21 Dec 2020 Phase-II/III clinical trials in Malaria (In infants, In neonates) in Mali, Democratic Republic of the Congo (PO) (NCT04300309)